SubHero Banner
Text

Tybost ® (cobicistat) – Expanded indication

August 22, 2019 - The FDA approved Gilead’s Tybost (cobicistat), to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of human immunodeficiency virus (HIV)-1 infection in pediatric patients weighing at least 35 kg.

Download PDF